美国的辅助生殖技术医疗(ART)市场:各产品，各技术，患者各类型，各终端用户，各地区，机会，预测，2018年～2032年

美国辅助生殖技术 (ART) 市场规模预计将从 2024 年的 62.8 亿美元增长至 2032 年的 95.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.40%。市场成长的推动因素包括：越来越多的人倾向于推迟生育，生活方式和饮食习惯的改变导致不孕症病例增加，以及人们对市场上各种不孕症治疗方法的认识不断提高。根据美国疾病管制与预防中心的估计，约有 13.4% 的 15-49 岁女性患有不孕症。

在美国，同性伴侣数量的增加和单亲家庭的日益增长，进一步增加了对 ART 的依赖。卵子捐赠和精子库已成为公认的第三方生殖方法，而妊娠代孕在美国多个州也获得了法律和社会的认可。生育诊所正在扩大其捐赠库网路和代孕配对服务，以满足患者的多样化需求。然而，由于涉及伦理和法律的复杂性，这些安排也带来了许多课题。儘管如此，这些领域的透明度正在提高，标准化框架也确保了患者和捐赠者的权益。

本报告提供美国的辅助生殖技术医疗(ART)市场相关调查，提供市场概要，以及产品，各技术，患者各类型，各终端用户，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 美国的辅助生殖技术医疗(ART)市场预测，2018年～2032年

• 市场规模分析与预测
• 市场占有率分析与预测
  • 各产品
    • 设备
    • 消耗品
    • 试剂和培养基
  • 各技术
    • 体外受精(IVF)
    • 人工授精(AI-IUI)
    • 冻结胚移植(FER)
    • 其他
  • 患者各类型
    • 男性
    • 女性
  • 各终端用户
    • 不孕治疗诊所
    • 医院
    • 外科中心
    • 临床研究机关
    • 其他
  • 各地区
    • 东北部
    • 中西部
    • 西部
    • 南部
  • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
• 2024年的市场地图分析

第6章 需求供给分析

第7章 进出口的分析

第8章 价值链分析

第9章 波特的五力分析

第10章 大环境分析

第11章 价格分析

第12章 市场动态

• 市场促进因素
• 市场课题

第13章 市场趋势与发展

第14章 法规结构和革新

• 法规当局的认证

第15章 专利的形势

第16章 案例研究

第17章 竞争情形

• 前五名市场领导的竞争矩阵
• 前五名参与企业的SWOT分析
• 前10名市场主要企业的形势
  • CooperSurgical, Inc.
  • Thermo Fisher Scientific Inc.
  • FUJIFILM Irvine Scientific, Inc.
  • Cook Group Incorporated
  • Vitrolife, Inc.
  • Hamilton Thorne Inc.
  • Ferring B.V.
  • Genea Group
  • Esco Lifesciences Group Ltd.
  • Kitazato Corporation

第18章 策略性建议

第19章 关于调查公司·免责声明

United States assisted reproductive technology (ART) market is projected to witness a CAGR of 5.40% during the forecast period 2025-2032, growing from USD 6.28 billion in 2024 to USD 9.56 billion in 2032. The market's growth can be attributed to the increasing preference for delaying parenthood, rising cases of infertility due to changing lifestyle and eating habits and increasing awareness about the different fertility solutions available in the market. As per the estimates of the Center for Disease Control and Prevention, approximately 13.4% of women of ages 15-49 have impaired fertility.

The increasing number of same-sex couples, along with increasing preference for single parenthood in the United States, are further propelling the reliance on ART in the country. Egg donation and sperm banking have become accepted practices as third-party reproductive modes, and gestational surrogacy has gained legal and social acceptance in several states across the country. Fertility clinics are expanding their networks of donor banks and surrogate-matching services to accommodate the distinctive requirements of diverse patient populations. The ethical and legal intricacies associated with any of these arrangements, however, do present some challenges; nevertheless, transparency in these areas is on the rise due to the framework of standardization to ensure the protection of both patients and donors alike.

Increasing Investments Boost Market Growth

Investments in ART are enabling the expansion of fertility clinics, improving treatment accessibility, and advancements in medical technologies. Availability of capital supports research and development activities, resulting in higher success rates for artificial insemination and IVF, among other procedures. Additionally, investments also allow fertility clinics to modernize and expand their facilities, allowing them to provide high-quality care to the patient population.

In May 2023, Morgan Health (a JPMorgan Chase & Co. business unit) invested USD 25 million in Kindbody, a leading fertility clinic network, to expand the accessibility of high-quality reproductive healthcare services for employees across the United States to combat the growing threat of infertility.

Technological Advancements Support Market Expansion

Growing emphasis on technological innovations is driving the market's growth and bolstering the availability of technological solutions such as time-lapse embryo imaging, artificial intelligence-assisted embryo selection, non-invasive preimplantation genetic testing (niPGT), and advanced cryopreservation techniques. Artificial intelligence and machine learning tools are becoming increasingly useful in identifying the most viable embryos for implantation, thereby reducing cycle failure rates and improving live birth outcomes. Robot-assisted minimally invasive procedures make egg retrievals and embryo transfer more comfortable for patients and enable faster recovery. These technological improvements are making ART more accessible, efficient, and personalized, thus allowing the market players to expand their customer base.

Additionally, leading ART service providers are also focusing on collaborations to ensure the delivery of advanced technologies and services. For instance, in October 2024, Cryoport, Inc. partnered with TMRW Life Sciences, Inc. to provide fertility clinics with advanced solutions for secure transportation and management of the specimen.

Fertility Clinics Hold Major Market Share

Fertility clinics hold a major share of the market in the United States as they offer a broad range of fertility services, including fertility ART procedures, donor services, and counseling. The specialized workforce, state-of-the-art laboratories, and individual treatment protocols make clinics the preferred option for patients. Many clinics have cooperative agreements and are part of growing fertility networks supported by private equity firms, thus leading to greater consolidation and expansion. Such consolidation allows for greater service scalability, enhanced quality assurance, and regional and national brand marketing, allowing them to expand their market presence. Additionally, various fertility clinics are also focusing on developing digital patient portals, using mobile applications for tracking treatment adherence, and artificial intelligence-based cycle management platforms to make the treatment journey smoother, thus allowing the segment's expansion. Furthermore, various fertility clinics are also focusing on partnerships and collaborations to ensure the provision of advanced treatment solutions to the patient population.

For instance, in April 2024, First Fertility, one of the largest fertility networks in the United States, expanded its nationwide presence by partnering with Fertility & Surgical Associates of California (FSAC), a leading fertility practice known for advanced treatments. The collaboration aims to combine First Fertility's comprehensive, patient-centered care model with FSAC's expertise and advanced technology, enhancing access to state-of-the-art reproductive healthcare in the region.

Impact of the U.S. Tariffs on United States Assisted Reproductive Technology (ART) Market

The recently imposed tariffs have resulted in significant challenges for the ART market in the United States. The tariffs, aimed at boosting domestic manufacturing, have resulted in supply chain disruptions and increased costs for raw materials within the industry.

The tariffs are expected to bolster the costs of essential equipment and consumables for ART, including specialized laboratory equipment, cryopreservation media, and incubators. These increased costs are expected to cause hindrances for small and medium-sized fertility clinics that may struggle to absorb the increased expenses. Thus, affecting the affordability of the treatment solutions, limiting access to ART.

Key Players Landscape and Outlook

The market's key players are focusing on launching next-generation solutions to bolster the effectiveness of reproductive technologies. For instance, in July 2023, Thermo Fisher Scientific Inc. launched the Ion AmpliSeq Polyploidy Kit and the Ion ReproSeq PGT-A Kit for supporting preimplantation genetic testing-aneuploidy (PGT-A), commonly used to inform intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) research. PGT-A testing is used to identify chromosomal abnormalities in embryos. Such launches are expected to enhance the probability of successful pregnancies and improve reproductive health outcomes for future generations by providing researchers with deeper genomic insights.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Assisted Reproductive Technology (ART) Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Instruments
      • 5.2.1.1.1. Sperm Separators
      • 5.2.1.1.2. Embryo Incubators
      • 5.2.1.1.3. Cryosystems
      • 5.2.1.1.4. Other Instruments
    • 5.2.1.2. Consumables
      • 5.2.1.2.1. Culture Dishes and Plates
      • 5.2.1.2.2. Storage Vials
      • 5.2.1.2.3. Needles
      • 5.2.1.2.4. Embryo transfer Catheters
      • 5.2.1.2.5. Other Consumables
    • 5.2.1.3. Reagents and Media
      • 5.2.1.3.1. Embryo Culture Media
      • 5.2.1.3.2. Cryopreservation Media
      • 5.2.1.3.3. Semen Processing Media
  • 5.2.2. By Technology
    • 5.2.2.1. In-vitro Fertilization (IVF)
    • 5.2.2.2. Artificial Insemination (AI-IUI)
    • 5.2.2.3. Frozen Embryo Replacement (FER)
    • 5.2.2.4. Other Technologies
  • 5.2.3. By Patient Type
    • 5.2.3.1. Male
    • 5.2.3.2. Female
  • 5.2.4. By End-user
    • 5.2.4.1. Fertility Clinics
    • 5.2.4.2. Hospitals
    • 5.2.4.3. Surgical Centers
    • 5.2.4.4. Clinical Research Institutes
    • 5.2.4.5. Others
  • 5.2.5. By Region
    • 5.2.5.1. Northeast
    • 5.2.5.2. Midwest
    • 5.2.5.3. West
    • 5.2.5.4. South
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product
  • 5.3.2. By Technology
  • 5.3.3. By Patient Type
  • 5.3.4. By End-user
  • 5.3.5. By Region

6. Demand Supply Analysis

7. Import and Export Analysis

8. Value Chain Analysis

9. Porter's Five Forces Analysis

10. PESTLE Analysis

11. Pricing Analysis

12. Market Dynamics

• 12.1. Market Drivers
• 12.2. Market Challenges

13. Market Trends and Developments

14. Regulatory Framework and Innovation

• 14.1. Regulatory Approvals

15. Patent Landscape

16. Case Studies

17. Competitive Landscape

• 17.1. Competition Matrix of Top 5 Market Leaders
• 17.2. SWOT Analysis for Top 5 Players
• 17.3. Key Players Landscape for Top 10 Market Players
  • 17.3.1. CooperSurgical, Inc.
    • 17.3.1.1. Company Details
    • 17.3.1.2. Key Management Personnel
    • 17.3.1.3. Products and Services
    • 17.3.1.4. Financials (As Reported)
    • 17.3.1.5. Key Market Focus and Geographical Presence
    • 17.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 17.3.2. Thermo Fisher Scientific Inc.
  • 17.3.3. FUJIFILM Irvine Scientific, Inc.
  • 17.3.4. Cook Group Incorporated
  • 17.3.5. Vitrolife, Inc.
  • 17.3.6. Hamilton Thorne Inc.
  • 17.3.7. Ferring B.V.
  • 17.3.8. Genea Group
  • 17.3.9. Esco Lifesciences Group Ltd.
  • 17.3.10. Kitazato Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

18. Strategic Recommendations

19. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Assisted Reproductive Technology (ART) Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Assisted Reproductive Technology (ART) Market Share (%), By Product, 2018-2032F
• Figure 3. United States Assisted Reproductive Technology (ART) Market Share (%), By Technology, 2018-2032F
• Figure 4. United States Assisted Reproductive Technology (ART) Market Share (%), By Patient Type, 2018-2032F
• Figure 5. United States Assisted Reproductive Technology (ART) Market Share (%), By End-User, 2018-2032F
• Figure 6. United States Assisted Reproductive Technology (ART) Market Share (%), By Region, 2018-2032F
• Figure 7. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Patient Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 10. By End-User Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024